Targeting gut microbiota and arginase boosts MEK inhibitors’ enhancement of antitumour immunity via MHC-I upregulation in colorectal cancer



Summary

MEK inhibitors, while promising for colorectal cancer (CRC) treatment, often face limited efficacy. This study reveals that combining MEK inhibitors with strategies targeting the gut microbiota and arginase significantly enhances their ability to stimulate anti-tumor immunity. Specifically, modulating gut microbiota and inhibiting arginase leads to increased levels of MHC-I, a key molecule for presenting tumor antigens to immune cells. This MHC-I upregulation, driven by MEK inhibitors in combination with gut and arginase modulation, results in a stronger cytotoxic T-cell response against CRC cells, ultimately leading to improved anti-tumor efficacy.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!